CivicaScript, a unit of hospital-owned nonprofit drug company Civica Rx, has launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer. The company will sell abiraterone to pharmacies at $160 for one month’s supply and recommends selling it to patients for no more than $171, a 6.9% mark-up.
Patients with Medicare Part D—the most likely payor for medications treating this type of cancer—pay about $3,000 per month for abiraterone on average, CivicaScript says. A generic version was first released in 2018 but lacks sufficient market competition to make it affordable for most patients.
CivicaScript, a unit of hospital-owned nonprofit drug company Civica Rx, has launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
